# Phosphoinositide 3-kinase δ activity in patients with systemic lupus erythematosus

**Authors:** Elham Sadat Mirfazeli, Shalmalee Kharkar, Michel W. P. Tsang-A-Sjoe, Olivier Papapietro, Izabella Niewczas, Agner R. Parra Sanchez, Anita Chandra, Klaus Okkenhaug, Irene E. M. Bultink, Reina E. Mebius, Jonathan Clark, Alexandre E. Voskuyl, Sergey Nejentsev

PMC · DOI: 10.3389/fimmu.2026.1745692 · Frontiers in Immunology · 2026-02-17

## TL;DR

This study explores PI3Kδ activity in T cells from SLE patients and finds that only a small subset shows increased activity, similar to a rare genetic disorder.

## Contribution

Identifies a subset of SLE patients with elevated PI3Kδ activity, suggesting potential for targeted treatment.

## Key findings

- Most SLE patients did not show increased PI3Kδ activity compared to healthy controls.
- A small subset of SLE patients exhibited PIP3 levels comparable to those in an APDS patient.
- PIP3 levels correlated with specific T-cell populations, indicating possible immune dysregulation.

## Abstract

New biomarkers are needed for better stratification and personalized treatment of Systemic Lupus Erythematosus (SLE). Phosphoinositide 3-kinase δ (PI3Kδ) has been implicated in SLE pathogenesis. Here, we investigated whether a subset of SLE patients has increased PI3Kδ activity after T cell activation.

T cells were isolated from frozen PBMCs of 108 SLE patients, 19 healthy controls, and one patient with Activated PI3K Delta syndrome (APDS), which provided a benchmark of increased PI3Kδ activity. After 90-minute anti-CD3/CD28 stimulation, phosphatidylinositol 3,4,5-trisphosphate (PIP3) and phosphatidylinositol 4,5-bisphosphate (PIP2) were measured using high-performance liquid chromatography-mass spectrometry.

Higher levels of PIP3 (measured as the ratio of PIP3/PIP2) in stimulated T cells distinguished APDS patient from other subjects providing a useful biomarker of increased PI3Kδ activity. We observed no significant difference in T-cell PIP3 levels between SLE patients and healthy controls. However, a subset of SLE patients (n = 4) exhibited strong upregulation of PIP3 following T-cell stimulation, comparable to that observed in the APDS patient. PIP3 levels in stimulated T cells positively correlated with the frequency of CD4+ T cells and negatively correlated with the frequencies of CD8+, EMRA CD4+, and EMRA CD8+ T cells.

We describe the range of variation of PI3Kδ activity in T cells from a large cohort of patients with SLE and from healthy subjects. Our findings suggest that increased PI3Kδ activity is not associated with SLE in general, although some SLE patients exhibit a particularly strong upregulation of PIP3 levels after T-cell stimulation. This subgroup of SLE patients warrants further investigation given the promising effect of PI3Kδ inhibitors in restoring normal immune regulation.

## Linked entities

- **Proteins:** CD4 (CD4 molecule), CD8A (CD8 subunit alpha)
- **Chemicals:** phosphatidylinositol 3,4,5-trisphosphate (PubChem CID 643963), PIP3 (PubChem CID 53477782), phosphatidylinositol 4,5-bisphosphate (PubChem CID 5311358), PIP2 (PubChem CID 5311358)
- **Diseases:** Systemic Lupus Erythematosus (MONDO:0007915), SLE (MONDO:0007915), Activated PI3K Delta syndrome (MONDO:0018338), APDS (MONDO:0018338)

## Full-text entities

- **Genes:** CXCR5 (C-X-C motif chemokine receptor 5) [NCBI Gene 643] {aka BLR1, CD185, MDR15}, PIK3CD (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta) [NCBI Gene 5293] {aka APDS, IMD14, IMD14A, IMD14B, P110DELTA, PI3K}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CD27 (CD27 molecule) [NCBI Gene 939] {aka S152, S152. LPFS2, T14, TNFRSF7, Tp55}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, Pik3cd (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta) [NCBI Gene 18707] {aka 2410099E07Rik, 2610208K16Rik, p110delta}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, TEC (tec protein tyrosine kinase) [NCBI Gene 7006] {aka PSCTK4}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, Cd247 (CD247 antigen) [NCBI Gene 12503] {aka 4930549J05Rik, A430104F18Rik, Cd3, Cd3-eta, Cd3-zeta, Cd3h}, Igh-V7183 (immunoglobulin heavy chain (V7183 family)) [NCBI Gene 16059] {aka B9-scFv, IgG, IgH, IgVH1(VSG), VH7183, VI24H}, CD24 (CD24 molecule) [NCBI Gene 100133941] {aka CD24A}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}
- **Diseases:** immune dysregulation (OMIM:614878), APDS (OMIM:615513), inborn error of immunity (MESH:D007154), COVID-19 (MESH:D000086382), glomerulonephritis (MESH:D005921), immunodeficiency (MESH:D007153), Pan T (MESH:C537931), SLE (MESH:D008180), autoimmune (MESH:D001327), nephritis (MESH:D009393), autoimmune manifestations (MESH:D012877), fatigue (MESH:D005221), inflammatory disease (MESH:D007249), respiratory tract infections (MESH:D012141), pain (MESH:D010146)
- **Chemicals:** DMSO (MESH:D004121), phosphatidylinositol 3,4,5-trisphosphate (MESH:C060974), Leniolisib (MESH:C000625376), 11131D (-), biotin (MESH:D001710), phospholipid (MESH:D010743), water (MESH:D014867), PIP2 (MESH:D019269), nitrogen (MESH:D009584), Phosphoinositides (MESH:D010716)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** E81K
- **Cell lines:** EMRA T — Mus musculus (Mouse), Hybridoma (CVCL_N292)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953358/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953358/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953358/full.md

---
Source: https://tomesphere.com/paper/PMC12953358